Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. Small-cap stocks experienced a bit of a disappointing quarter as both growth and value indexes saw negative quarterly returns for the first time since the pandemic-led market selloff in the early part of 2020. In a continuation of the recent trend, the Russell 2000® Growth Index (down 5.65%) trailed its Russell 2000® Value Index (down 2.98%) counterpart once again, with this quarter now marking four consecutive quarters of underperformance for growth. You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.
Carillon Tower Advisers, in its Q3 2021 investor letter, mentioned Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) and discussed its stance on the firm. Dicerna Pharmaceuticals, Inc. is a Lexington, Massachusetts-based biotechnology company with a $1.7 billion market capitalization. DRNA delivered a 1.09% return since the beginning of the year, while its 12-month returns are up by 1.09%. The stock closed at $22.27 per share on November 8, 2021.
Here is what Carillon Tower Advisers has to say about Dicerna Pharmaceuticals, Inc. in its Q3 2021 investor letter:
“Dicerna Pharmaceuticals is a biotechnology company focused on a gene silencing technology platform that addresses rare diseases. The firm’s shares suffered a selloff after posting mixed results in its trial of nedosiran, which is an RNAi therapeutic for primary hyperoxaluria (PH). Despite meeting the primary endpoint in the trial, efficacy data for one of the potential patient groups failed to demonstrate benefit over a placebo.”
Billion Photos/Shutterstock.com
Based on our calculations, Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds.DRNA was in 27 hedge fund portfolios at the end of the first half of 2021, compared to 27 funds in the previous quarter. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) delivered a -6.55% return in the past 3 months.
Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by 115 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.
At Insider Monkey, we scour multiple sources to uncover the next great investment idea. Lithium prices have more than doubled over the past year, so we are checking out this emerging lithium stock. We go through lists like the 10 best growth stocks to buy to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage.
Disclosure: None. This article is originally published at Insider Monkey.
